Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania

home / authors / joshua-m-bauml-md-perelman-school-of-medicine-university-of-pennsylvania

Articles

MET Inhibitors in NSCLC: Toxicity Management

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

April 19th 2021

Drs Joshua M. Bauml and Benjamin Levy highlight more common adverse events associated with MET inhibitors used to treat MET exon 14 skipping mutations in non–small cell lung cancer and share strategies to help manage patients on therapy.

MET Inhibitors in NSCLC: Treatment Selection

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

April 19th 2021

A comparison between the MET inhibitors available to treat MET exon 14 skipping mutations in non–small cell lung cancer and factors that should be considered when selecting a type 1 or type 2 MET-directed therapy.

Advances in Targeting MET Exon 14 Skipping Mutations in NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

March 29th 2021

Drs Joshua M. Bauml and Benjamin Levy react to the development of novel therapies that specifically target MET exon 14 skipping mutations in non–small cell lung cancer.

MET Exon 14 Skipping Mutations in NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

March 29th 2021

Drs Joshua M. Bauml and Lyudmila A. Bazhenova describe what is understood regarding the behavior of MET exon 14 skipping mutations in non–small cell lung cancer and remark on their prevalence among specific patient populations.